# Epizyme, Inc.: Phase 3 study closed enrollment, 599 enrolled (Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Epizyme, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
| NCT ID | NCT04224493 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma |
| Intervention types | drug, combination product |
| Target enrollment | 599 |
| Site countries | United States, Australia, Belgium, Brazil, Canada, China, France, Germany, Hungary, Italy, Poland, Singapore |
| Posted | 2020-01-13 |
| Planned start | 2020-06-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-05 |
| Last update posted | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 599 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04224493). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.